mailitics

Category: Drug prices

  • STAT+: HHS tries pushing pharma to the negotiating table

    STAT+: HHS tries pushing pharma to the negotiating table Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today, we’re hearing more about President Trump’s “most-favored nation” plan for drug pricing, Recursion’s case for why the company laid off 20% of…

  • The upheaval of CDC’s vaccine panel, and drug pricing confusion

    The upheaval of CDC’s vaccine panel, and drug pricing confusion Why did Robert F. Kennedy Jr. abruptly fire all members of the expert panel that advises the Centers for Disease Control and Prevention on vaccines? Who are the new members that Kennedy named? And what does that all mean for the future of public health?…

  • STAT+: Cassidy is circulating a proposed law to push down U.S. drug prices, backing a key Trump ambition

    STAT+: Cassidy is circulating a proposed law to push down U.S. drug prices, backing a key Trump ambition WASHINGTON — Senate health committee Chair Bill Cassidy (La.) is the latest Republican to take an interest in legislation that would tie U.S. brand drug prices to lower prices in other wealthy countries, according to seven people…

  • After groundbreaking CRISPR therapy, a homecoming

    After groundbreaking CRISPR therapy, a homecoming Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! Baby KJ is back home! Also, we discuss the questionable efficacy of ctDNA blood tests, see what Vinay Prasad has to say at NORD, and more.  Read…

  • Pluvicto pushes earlier in prostate cancer play

    Pluvicto pushes earlier in prostate cancer play Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, STAT’s Matthew Herper chats with J&J’s R&D chief, we see the radiopharmaceutical Pluvicto being considered earlier for prostate cancer, and more.  Read the rest… Meghana…

  • Illumina’s PromoterAI unlocks rare disease clues in noncoding genome

    Illumina’s PromoterAI unlocks rare disease clues in noncoding genome Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today, we discuss how one Brown contrarian and cancer researcher wants $50 billion for the NCI, we see a UniQure case study that…

  • Post-TIGIT flop, iTeos Therapeutics is shuttering

    Post-TIGIT flop, iTeos Therapeutics is shuttering Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we look at the implications of BARDA cutting a major vaccine contract with Moderna, hear why former FDA chief Scott Gottlieb thinks agency layoffs will impede…

  • Opinion: Former FDA commissioner: ‘Cost-cutting’ may undo one of Trump’s best drug pricing achievements

    Opinion: Former FDA commissioner: ‘Cost-cutting’ may undo one of Trump’s best drug pricing achievements President Trump often touted during his first term that his administration had “approved more affordable generic drugs than any administration in history.” He had good reason to highlight these accomplishments. Over the first two years of his presidency, the Food and…

  • Lilly to acquire biotech developing pain drugs

    Lilly to acquire biotech developing pain drugs Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, we’re seeking nominations for our annual Wunderkinds list, which aims to honor some of the most promising early-career scientists out there. If you have someone in mind, submit…

  • GSK drug’s new approval sets up competition with Dupixent

    GSK drug’s new approval sets up competition with Dupixent Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Apologies that this newsletter is coming late to you this morning — we had some technical difficulties. But we’ve still got the news…

  • Trump’s drug-pricing plan and a potential Theranos 2.0

    Trump’s drug-pricing plan and a potential Theranos 2.0 How likely is it for President Trump’s new drug-pricing plan to be implemented? Why have investors seemed unbothered by the proposal? And will we see a return of Elizabeth Holmes’ blood-testing ambitions? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s…

  • FDA approves Verastem’s ovarian cancer treatment

    FDA approves Verastem’s ovarian cancer treatment Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk about the FDA’s new artificial intelligence effort in the wake of mass layoffs, see AI darling Insitro cut staff, and more. Read the rest… Meghana…

  • More proposed cuts to the NIH

    More proposed cuts to the NIH Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we talk about Arkansas making a bold move to curb PBM power, analyze Trump’s executive order in regards to drug prices, and more. Read the rest… Meghana…

  • Pfizer discontinues its experimental GLP-1 pill

    Pfizer discontinues its experimental GLP-1 pill Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we discuss interesting new gene-editing data from Verve, see the NIH starting to convene advisory councils again, and more. Read the rest… Meghana Keshavan Go to statnews

  • STAT+: Tennessee officials find Express Scripts violated law governing commercial pharmacy claims

    STAT+: Tennessee officials find Express Scripts violated law governing commercial pharmacy claims In an unusual move, an audit of commercial health plans by Tennessee officials found that Express Scripts, one of the largest pharmacy benefit managers in the United States, violated state laws in its dealings with pharmacies, according to newly released documents. Specifically, the…

  • NIH hit with chaos, cuts, and contractor purge

    NIH hit with chaos, cuts, and contractor purge Hello. Today, we dive into the implications of the ongoing cuts to various health and science agencies….It’s a doozy. Oh, and if you like talking about neuroscience and happen to be near San Diego this weekend, come hang with me and my colleagues at STAT@AAN: The Future…

  • Emotional whiplash for PTC Therapeutics

    Emotional whiplash for PTC Therapeutics Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we process the shockwaves in biotech following the ouster of CBER chief Peter Marks, see a radiopharmaceutical expand its reach, and more. Read the rest… Meghana Keshavan…